Stryker (NYSE:SYK) Issues Earnings Results

Stryker (NYSE:SYK) posted its quarterly earnings results on Thursday. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03), FiscalAI reports. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion.

Here are the key takeaways from Stryker’s conference call:

• Hip and knee weakness pressured results: Stryker said the large-joint market has slowed to roughly 2.5% growth, citing affordability concerns, insurance-related preauthorization denials and softer international conditions. The company also acknowledged that cyber and SAP implementation disruptions hurt commercial execution and new-product adoption.
• Stryker lowered its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, reflecting weaker hip and knee trends, lingering peripheral vascular supply constraints and a more conservative view of capital-equipment execution.
• Margins and cash generation remained strong: Third-quarter adjusted EPS rose 10.3% to $3.52, adjusted operating margin expanded 60 basis points to 26.2%, and year-to-date operating cash flow increased about 14% to $3.3 billion. The board also authorized an additional $3 billion for share repurchases.
• MedSurg and Neurotechnology grew 9.1%, led by Endoscopy, Medical and Vascular, while capital demand and the order book remained elevated. Stryker expects strong fourth-quarter contributions from Trauma and Extremities, Medical and Instruments, and highlighted upcoming growth drivers including AVS, new power-tool and endoscopy platforms, Mako products and the CMR Surgical robotics partnership.

Stryker Stock Performance

Shares of SYK traded up $7.12 during mid-day trading on Thursday, hitting $311.12. The stock had a trading volume of 3,059,300 shares, compared to its average volume of 2,454,501. The company has a market cap of $119.33 billion, a PE ratio of 32.24, a PEG ratio of 1.98 and a beta of 0.78. The company’s fifty day simple moving average is $294.14 and its two-hundred day simple moving average is $325.14. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker has a fifty-two week low of $267.00 and a fifty-two week high of $389.33.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter sales increased 7.7%, reflecting continued demand for Stryker’s medical equipment and products. Management also highlighted recovery progress following the cybersecurity incident disclosed earlier in 2026. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management expects 2026 organic net sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. Stryker’s latest analyst price targets remain above the current trading level, but those targets may be revised after the outlook reduction. Stryker Q3 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted third-quarter EPS was $3.52, below the $3.55 consensus estimate, while revenue of $6.52 billion missed expectations of $6.62 billion. Quarterly profit declined year over year, indicating that revenue growth was not sufficient to offset margin and operating pressures. Stryker Lowers Outlook After 3Q Profit Falls
• Negative Sentiment: The company lowered its prior 2026 forecasts from 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS. Investors are also monitoring manufacturing constraints affecting the vascular business, along with lingering effects from the cybersecurity incident. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Recent insider activity shows reported sales without purchases over the past six months, including substantial selling by director Ronda E. Stryker. While insider transactions may be unrelated to near-term fundamentals, the pattern can add to investor caution.

Insider Buying and Selling at Stryker

In related news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. TD Cowen cut their target price on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. BTIG Research lowered their price target on Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Citigroup dropped their price target on Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, September 10th. Raymond James Financial set a $370.00 price objective on Stryker in a report on Friday, July 31st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $317.00 price objective on shares of Stryker in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.